Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 473-477

  Abbate, Eduardo ^a   Vescovo, Marisa ^a   Natiello, Marcela ^a   Cufré, Mónica ^a   García, Ana ^a   Montaner, Pablo Gonzalez ^a   Ambroggi, Marta ^a   Ritacco, Viviana ^b,c   Van soolingen, Dick ^d,e  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse effects; Fluoroquinolones; Phenothiazines; Toxicity; Treatment outcome

Indexed keywords

LINEZOLID; MOXIFLOXACIN; THIORIDAZINE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARGENTINA; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; MALE; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PANCYTOPENIA; RETROSPECTIVE STUDY; SKIN ALLERGY;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; ARGENTINA; AZA COMPOUNDS; COMPASSIONATE USE TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; QUINOLINES; RETROSPECTIVE STUDIES; THIORIDAZINE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84855829764     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr500     Document Type: Article

References (10)

1. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
2. van Helden PD, Victor T, Warren RM. The "source" of drug-resistant TB outbreaks. Science 2006; 314: 419-20.
3. Schecter GF, Scott C, True L et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
4. Sotgiu G, Lange C, Richardson MD et al. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 879-83; authors' response 883-4.
5. Abbate E, Brea A, Cufré M et al. Linezolid in multidrug-resistant tuberculosis treatment. Eur Respir J 2004; 24 Suppl 48: 485s.
6. Williams KN, Stover CK, Zhu T et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-9.
7. Poissy J, Aubry A, Fernandez C et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-71.
8. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
9. Amaral L, Boeree MJ, Gillespie SH et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35: 524-6.
10. Udwadia ZF, Sen T, Pinto LM. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov 2011; 6: 88-91.